Nkarta (NKTX) – Research Analysts’ Weekly Ratings Updates

Nkarta (NASDAQ: NKTX) recently received a number of ratings updates from brokerages and research firms:

• 8/15/2026 – Nkarta was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 8/14/2026 – Nkarta had its price target lowered by Stifel Nicolaus from $11.00 to $10.00. They now have a “buy” rating on the stock.
• 8/11/2026 – Nkarta had its price target lowered by HC Wainwright to $14.00. They now have a “buy” rating on the stock.
• 8/2/2026 – Nkarta was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 7/25/2026 – Nkarta was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 6/24/2026 – Nkarta had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 6/23/2026 – Nkarta is now covered by TD Cowen. They set a “buy” rating on the stock.

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.